BACKGROUND: Severe anaemia is a major complication of malaria but little is known about its pathogenesis. Experimental models have implicated tumour necrosis factor (TNF) in induction of bone-marrow suppression and eythrophagocytosis. Conversely, interleukin 10 (IL-10), which mediates feed-back regulation of TNF, stimulates bone-marrow function in vitro and counteracts anaemia in mice. We investigated the associations of these cytokines with malarial anaemia. METHODS: We enrolled 175 African children with malaria into two studies in 1995 and 1996. In the first study, children were classified as having severe anaemia (n=10), uncomplicated malaria (n=26), or cerebral anaemia (n=41). In the second study, patients were classified as having cerebral malaria (n=33) or being fully conscious (n=65), and the two groups were subdivided by measured haemoglobin as normal (>110 g/L), moderate anaemia (60-90 g/L), and severe anaemia (<50 g/L). IL-10 and TNF concentrations were measured by ELISA in plasma samples from all patients. FINDINGS: IL-10 concentrations were significantly lower in patients with severe anaemia than in all other groups. In 1995, geometric mean plasma IL-10 in patients with severe anaemia was 270 pg/mL (95% CI 152-482) compared with 725 pg/mL (465-1129) in uncomplicated malaria and 966 pg/mL (612-1526) in cerebral malaria (p<0.03). In 1996, fully conscious patients with severe anaemia also had significantly lower IL-10 concentrations than all other groups, including cerebral-malaria patients with severe anaemia and all patients with moderate anaemia (p<0.001). In both studies, TNF concentrations were significantly higher in cerebral malaria than in fully conscious patients (p<0.01). By contrast, the ratio of TNF to IL-10 was significantly higher in fully conscious patients with severe anaemia than in all other groups (p<0.001). INTERPRETATION: Our findings identify severe malarial anaemia as a distinct disorder in which insufficient IL-10 response to high TNF concentrations may have a central role.
BACKGROUND: Severe anaemia is a major complication of malaria but little is known about its pathogenesis. Experimental models have implicated tumour necrosis factor (TNF) in induction of bone-marrow suppression and eythrophagocytosis. Conversely, interleukin 10 (IL-10), which mediates feed-back regulation of TNF, stimulates bone-marrow function in vitro and counteracts anaemia in mice. We investigated the associations of these cytokines with malarial anaemia. METHODS: We enrolled 175 African children with malaria into two studies in 1995 and 1996. In the first study, children were classified as having severe anaemia (n=10), uncomplicated malaria (n=26), or cerebral anaemia (n=41). In the second study, patients were classified as having cerebral malaria (n=33) or being fully conscious (n=65), and the two groups were subdivided by measured haemoglobin as normal (>110 g/L), moderate anaemia (60-90 g/L), and severe anaemia (<50 g/L). IL-10 and TNF concentrations were measured by ELISA in plasma samples from all patients. FINDINGS:IL-10 concentrations were significantly lower in patients with severe anaemia than in all other groups. In 1995, geometric mean plasma IL-10 in patients with severe anaemia was 270 pg/mL (95% CI 152-482) compared with 725 pg/mL (465-1129) in uncomplicated malaria and 966 pg/mL (612-1526) in cerebral malaria (p<0.03). In 1996, fully conscious patients with severe anaemia also had significantly lower IL-10 concentrations than all other groups, including cerebral-malariapatients with severe anaemia and all patients with moderate anaemia (p<0.001). In both studies, TNF concentrations were significantly higher in cerebral malaria than in fully conscious patients (p<0.01). By contrast, the ratio of TNF to IL-10 was significantly higher in fully conscious patients with severe anaemia than in all other groups (p<0.001). INTERPRETATION: Our findings identify severe malarial anaemia as a distinct disorder in which insufficient IL-10 response to high TNF concentrations may have a central role.
Authors: Kåre Kemp; Jørgen A L Kurtzhals; Bartholomew D Akanmori; Victoria Adabayeri; Bamenla Q Goka; Charlotte Behr; Lars Hviid Journal: Clin Diagn Lab Immunol Date: 2002-05
Authors: Gerardo Cabrera; Clarisse Yone; Anne E Tebo; Jan van Aaken; Bertrand Lell; Peter G Kremsner; Adrian J F Luty Journal: Infect Immun Date: 2004-01 Impact factor: 3.441
Authors: Philip E Thuma; Janneke van Dijk; Rick Bucala; Zufan Debebe; Sergei Nekhai; Thea Kuddo; Mehdi Nouraie; Günter Weiss; Victor R Gordeuk Journal: J Infect Dis Date: 2011-01-15 Impact factor: 5.226
Authors: Peter D Crompton; Jacqueline Moebius; Silvia Portugal; Michael Waisberg; Geoffrey Hart; Lindsey S Garver; Louis H Miller; Carolina Barillas-Mury; Susan K Pierce Journal: Annu Rev Immunol Date: 2014 Impact factor: 28.527
Authors: Florence Burté; Biobele J Brown; Adebola E Orimadegun; Wasiu A Ajetunmobi; Nathaniel K Afolabi; Francis Akinkunmi; Olayinka Kowobari; Samuel Omokhodion; Kikelomo Osinusi; Felix O Akinbami; Wuraola A Shokunbi; Olugbemiro Sodeinde; Delmiro Fernandez-Reyes Journal: Blood Date: 2013-02-04 Impact factor: 22.113
Authors: K E Lyke; R Burges; Y Cissoko; L Sangare; M Dao; I Diarra; A Kone; R Harley; C V Plowe; O K Doumbo; M B Sztein Journal: Infect Immun Date: 2004-10 Impact factor: 3.441